What Is a Peptide? Structure, Function and Why It Matters in Research

Almost every research compound in the Wednesday catalog is a peptide, and the word is used so freely that its actual meaning is easy to lose. A peptide is a molecule built from amino acids linked end to end, short enough that it does not fold into the large, stable architecture we call a protein. That definition hides a great deal of chemistry. This note walks through what a peptide is at the level of atoms and bonds, how sequence gives rise to function, and why molecules of this size have become a central object of study in pharmacology, endocrinology and cell biology. It is written as the first stop in our foundations series, and it deliberately stays with the chemistry rather than any single compound.

The building blocks: amino acids

Every peptide begins with amino acids. Each is a small molecule with a central carbon (the alpha carbon) bonded to four things: an amino group (–NH₂), a carboxylic acid group (–COOH), a hydrogen atom, and a variable side chain usually written as R. The first three are identical across all standard amino acids; the side chain is what makes glycine different from tryptophan.¹

Twenty amino acids are encoded directly by the standard genetic code, and two more, selenocysteine and pyrrolysine, are inserted by specialized machinery in some organisms.² Side chains are grouped by their chemical character: nonpolar and hydrophobic (leucine, valine, phenylalanine), polar but uncharged (serine, threonine, asparagine), positively charged at physiological pH (lysine, arginine, histidine), negatively charged (aspartate, glutamate), and structurally unusual (glycine, with no real side chain; proline, whose side chain loops back onto the backbone nitrogen; cysteine, whose thiol can form disulfide bridges).

Because every amino acid except glycine has four different groups around its alpha carbon, each exists as two mirror-image forms. Biology uses the L-form almost exclusively, and synthetic chemists who want a peptide to resist enzymatic breakdown sometimes swap in a D-amino acid at a vulnerable position, since most proteases do not recognize the mirror image.³

The peptide bond

Two amino acids join when the carboxyl group of one condenses with the amino group of the next, releasing a molecule of water. The resulting C(=O)–NH linkage is an amide, and in this context it is called a peptide bond. The bond has partial double-bond character because electrons delocalize between the carbonyl oxygen and the amide nitrogen. This makes it planar and rigid: the six atoms around a peptide bond lie in one plane, and rotation about the bond is strongly disfavored.⁴

Two consequences follow. First, the backbone of a peptide is not a floppy chain; it is a series of rigid planar units connected at the alpha carbons, where rotation is permitted around two bonds (the phi and psi angles). The whole repertoire of secondary structure, including the alpha helix and beta sheet that Pauling, Corey and Branson described in 1951, emerges from the limited set of angles those two bonds can adopt without steric clashes.⁴ Second, the peptide bond is chemically stable under ordinary conditions. Hydrolysis is thermodynamically favorable but kinetically slow in water; in living systems it is proteases that do the work, and the half-life of a circulating peptide is set largely by how quickly those enzymes find their cleavage sites.³

A chain has direction. The end with the free amino group is the N-terminus; the end with the free carboxyl is the C-terminus. By convention sequences are written and numbered from N to C, so a sequence written Gly-Pro-Glu describes a specific molecule and Glu-Pro-Gly a different one.¹

Where a peptide stops being a peptide

There is no sharp chemical line between a peptide and a protein, and nomenclature bodies have never tried to draw one precisely. The IUPAC-IUB recommendations describe oligopeptides as containing a small number of residues and polypeptides as longer chains, and note that the term protein is generally used for polypeptides that occur naturally with a defined three-dimensional structure.¹ In practice, working scientists treat roughly 50 residues as the boundary. Below that, a chain typically lacks a stable fold on its own; above it, the chain can bury a hydrophobic core and hold a structure. Insulin, at 51 residues in two chains, sits right at the edge and is described as either, depending on who is speaking.

The distinction is not academic. It determines how the molecule is made (chemical synthesis versus recombinant expression), how it behaves in solution, how it is analyzed, and how regulators classify it. Our companion note on amino acids, peptides and proteins covers these lines in more detail.

Category	Typical length	Stable fold on its own?	Usual production route	Example
Dipeptide / tripeptide	2–3 residues	No	Chemical synthesis	Glutathione (3), GHK (3)
Oligopeptide	4–~20 residues	Rarely	Solid-phase synthesis	Oxytocin (9), BPC-157 (15)
Polypeptide	~20–50 residues	Sometimes (helical segments)	Synthesis or recombinant	Sermorelin (29), GLP-1 (30–31)
Protein	>50 residues	Yes	Recombinant expression	Insulin (51), growth hormone (191)

Sequence is function

The central idea of peptide chemistry is that sequence encodes behavior. Christian Anfinsen demonstrated in the 1960s and 1970s that a denatured protein can refold spontaneously to its native shape, meaning the information for three-dimensional structure is contained in the one-dimensional sequence.⁵ For short peptides the same principle operates at a smaller scale. The pattern of hydrophobic and charged residues determines whether a peptide will adopt a helix when it contacts a membrane or a receptor pocket, whether it will aggregate, how soluble it is, and what net charge it carries at a given pH.

Receptors read this information with remarkable specificity. Many peptide hormones act on G protein-coupled receptors, and the receptor binding site recognizes a handful of key residues arranged in a particular geometry. Change one residue and affinity may fall a thousandfold; add a single methyl group in the right place and the peptide may resist a protease that would otherwise destroy it in minutes.³ This is the logic behind most of the peptide analogues in the research literature: a natural sequence is taken as a template and edited to change its half-life, selectivity or potency.

A peptide is a sentence written in a twenty-letter alphabet, and the cell reads it one residue at a time.

Peptides as biological signals

The body uses peptides as messengers because they combine information density with disposability. A peptide can encode a very specific instruction in a short sequence, be released quickly, act on a receptor, and then be cleared by proteases within minutes so the signal does not linger. Hormones such as insulin, glucagon, oxytocin, vasopressin, growth hormone-releasing hormone and the incretins GLP-1 and GIP are all peptides. So are many neuropeptides, including substance P, the enkephalins and neuropeptide Y, and so are a large class of antimicrobial peptides that form part of innate immunity across species.⁶

Peptides also arise as fragments of larger proteins. Proteolytic processing of a precursor can liberate several distinct signaling peptides from one gene product, as happens with pro-opiomelanocortin, which yields ACTH, melanocyte-stimulating hormones and beta-endorphin. Some peptides that appear in research catalogs originate this way: thymosin beta-4 fragments, for instance, are segments of a larger actin-binding protein, and GHK is a tripeptide released from collagen breakdown.⁶

Why researchers work with peptides

Several properties make peptides useful tools rather than merely interesting molecules. Reviews of the field consistently point to the same set.^6,7,8

• Selectivity. Because they are recognized by receptors evolved for them, peptides tend to bind their targets with high affinity and few off-target interactions relative to small molecules.
• Synthetic access. Since Merrifield’s solid-phase method in 1963, any sequence up to a few dozen residues can be assembled chemically and modified at will, including with non-natural amino acids that recombinant systems cannot easily install. Our note on solid-phase peptide synthesis describes the process.
• Biological relevance. A synthetic copy of a native peptide lets researchers probe a signaling pathway with the same molecule the body uses, or with a defined variant of it.
• Low accumulation. Peptides are broken down to amino acids by ordinary metabolism, which is one reason they feature prominently in pharmacology research where clearance behavior matters.

The same properties bring limitations that shape experimental design. Peptides are generally poorly absorbed across the gut and are rapidly degraded in plasma, so much of the medicinal chemistry literature is devoted to extending half-life through lipidation, PEGylation, cyclization or D-amino acid substitution.^3,7 Their size also places most of them in a middle ground between small molecules and biologics, which complicates both analytics and regulation.

A brief history

The modern peptide era has three landmarks. Frederick Sanger’s sequencing of insulin, completed in the early 1950s, established that a protein has a single defined sequence and that this sequence could be determined experimentally.⁹ Vincent du Vigneaud’s chemical synthesis of oxytocin in 1953 proved that a biologically active peptide hormone could be built from scratch in the laboratory, work that earned the 1955 Nobel Prize in Chemistry.¹⁰ And Bruce Merrifield’s solid-phase method, published in 1963 and recognized with the 1984 Nobel Prize, turned peptide synthesis from a multi-year project into a routine procedure.¹¹

Since then, the number of peptide drugs approved by regulators has grown steadily, with more than 80 on the market worldwide and several hundred more in clinical trials as of recent surveys.^6,8 The compounds sold for research are, for the most part, either copies of these therapeutic candidates, copies of native signaling peptides, or synthetic sequences that first appeared in the preclinical literature.

What this means for research-grade material

For a peptide bought as a research chemical, the definitional points above translate into practical checks. Identity means the sequence in the vial matches the sequence claimed, which is confirmed by mass spectrometry. Purity means the fraction of peptide-containing material that is the intended sequence rather than truncated or modified variants, which is measured by HPLC. And because a peptide is a defined chemical entity rather than a biological extract, these measurements can be made precisely and reported on a certificate of analysis. Wednesday publishes these for each lot in the COA library. The remaining notes in this foundations series take each of these ideas in turn.

Frequently asked questions

What is a peptide in simple terms?

A peptide is a short chain of amino acids linked together by peptide bonds. It is smaller than a protein, typically fewer than about 50 amino acids, and usually does not fold into a fixed three-dimensional shape on its own. Many hormones and signaling molecules in the body are peptides.

What is the difference between a peptide and a protein?

Both are chains of amino acids. The difference is one of length and structure: proteins are longer (generally more than 50 residues) and fold into stable shapes, while peptides are shorter and more flexible. There is no strict chemical cutoff, and molecules near the boundary, such as insulin, are described either way.

How many amino acids make a peptide?

Two amino acids joined by a peptide bond make a dipeptide, the smallest peptide. Chains of up to about 20 residues are often called oligopeptides, and longer chains up to roughly 50 are polypeptides. Beyond that, the term protein is usually applied.

Are peptides natural or synthetic?

Both. The body produces thousands of peptides as hormones, neurotransmitters and protein fragments. Research peptides are typically made by chemical synthesis and may be exact copies of natural sequences or modified analogues designed to change stability or receptor selectivity.

Why are peptides studied so widely in research?

Peptides bind their receptors selectively, can be synthesized and modified precisely, and are the same class of molecule the body uses for signaling. That combination makes them useful tools for probing biological pathways, and it is why many drug candidates in development are peptides or peptide analogues.

References & further reading

1. IUPAC-IUB Joint Commission on Biochemical Nomenclature. Nomenclature and symbolism for amino acids and peptides. Recommendations 1983. Eur J Biochem. 1984;138(1):9-37. doi:10.1111/j.1432-1033.1984.tb07877.x / PMID 6743224
2. Ambrogelly A, Palioura S, Söll D. Natural expansion of the genetic code. Nat Chem Biol. 2007;3(1):29-35. doi:10.1038/nchembio847 / PMID 17173027
3. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. doi:10.1016/j.drudis.2014.10.003 / PMID 25450771
4. Pauling L, Corey RB, Branson HR. The structure of proteins: two hydrogen-bonded helical configurations of the polypeptide chain. Proc Natl Acad Sci USA. 1951;37(4):205-211. doi:10.1073/pnas.37.4.205
5. Anfinsen CB. Principles that govern the folding of protein chains. Science. 1973;181(4096):223-230. doi:10.1126/science.181.4096.223 / PMID 4124164
6. Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7:48. doi:10.1038/s41392-022-00904-4 / PMID 35165272
7. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8 / PMID 33536635
8. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. doi:10.1016/j.bmc.2017.06.052 / PMID 28720325
9. Sanger F, Tuppy H. The amino-acid sequence in the phenylalanyl chain of insulin. 1. The identification of lower peptides from partial hydrolysates. Biochem J. 1951;49(4):463-481. PMID 14886310
10. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879-4880. doi:10.1021/ja01115a553
11. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025